A patient who has received a new liver lives with a quiet question that no one can fully answer by looking: is the gift still healthy? Researchers at Georgetown and MedStar Health now suggest that a single blood draw might begin to answer it, by reading the faint genetic debris that dying cells leave in the bloodstream and tracing it back to where the injury began. In a medicine where a failing liver has no dialysis-like rescue, catching trouble in its earliest, quietest stage matters enormously, and this early study points toward a gentler way of listening to the body before it is too late.
Blood Test Can Spot Early Liver Transplant Rejection and Pinpoint Which Cells Are Being Damaged
Liver transplant patients face possible organ rejection or failure, with no dialysis-like backup and a limited supply of donor livers.
No machine or treatment can save a patient when the liver fails
Mark
Why does a blood test matter so much for liver transplants specifically?
Mimi
Because there's no backup. Kidneys can be supported with dialysis, but when a liver fails there's no machine that saves the patient, and donor livers are scarce.
Mark
What can doctors do now?
Mimi
Blood tests can flag possible damage, and genetic testing can say whether the injured cells are the donor's or the patient's. Finding the exact cause often means costly imaging or a biopsy.
Mark
So what's new here?
Mimi
The test reads chemical signatures on DNA fragments from dying cells, which point to the cell type and its location. Wellstein calls it the cellular origin of the damage.
Luke
Worth being clear about what's reported. This is a study describing the approach, and the source calls it a step toward a liquid biopsy, not a finished clinical test.
Mark
Kroemer says it could be more accurate than a needle biopsy.
Luke
He said potentially, and the reason he gave is sampling bias, since a biopsy takes one small core. The source gives no head-to-head accuracy figures, so that's a reasoned expectation, not a measured result.
Mimi
He also described how it could help: knowing the biliary side is injured but not the hepatocellular side would allow more personalized treatment.
Luke
Right, but that's an illustration. We don't know yet how it changes patient outcomes, or how many patients were tested.
Mark
And what's next?
Mimi
Other transplants, breast cancer radiation, melanoma, and a search for industry partners to commercialize it.
El Pulso
- A new liver can be quietly injured by surgery, immune attack or strain on nearby organs, and the signs often arrive before anyone knows where the damage lies.
- Today's answers require costly imaging or invasive biopsies, and a biopsy's single small core of tissue can miss the very damage it seeks.
- Researchers have shown that DNA fragments from dying cells in a blood sample can reveal not only that injury exists but which cell type and organ it came from.
- Because a blood draw is simple, the test could be repeated often, letting doctors choose personalized treatment early.
- The team has filed patents and is now seeking industry partners to commercialize the test, while exploring other transplants, cancer radiation and melanoma.
A patient who has received a new liver lives with a quiet question that no one can fully answer by looking: is the gift still healthy? Researchers at Georgetown and MedStar Health now suggest that a single blood draw might begin to answer it, by reading the faint genetic debris that dying cells leave in the bloodstream and tracing it back to where the injury began. In a medicine where a failing liver has no dialysis-like rescue, catching trouble in its earliest, quietest stage matters enormously, and this early study points toward a gentler way of listening to the body before it is too late.
A single tube of blood, drawn from a liver transplant patient, may soon reveal whether the new organ is in trouble and which of its cells are being hurt. Researchers at Georgetown University and MedStar Health have reported this early step toward a liquid biopsy in Nature Communications, published June 17.
The stakes are unusually high with the liver. When a kidney falters, dialysis can hold a patient steady, but no machine can replace a failing liver, and donor livers are scarce. Protecting each transplanted organ is therefore a priority, as transplant surgeon and co-author Alexander Kroemer emphasized.
The new method reads DNA fragments from the debris of dying cells circulating in the blood. Senior author Anton Wellstein explained that the chemical signatures on these fragments reveal the cell type they came from, whether in the transplanted liver or elsewhere in the body. Because a blood draw is easy, the test can be repeated often, and Kroemer noted it may be more accurate than a needle biopsy, which examines only one small core of tissue.
The work began seven years ago, supported by a $2.5 million National Institutes of Health grant and launched by first author Megan McNamara. Georgetown has filed patents, and the team is now studying other transplants, breast cancer radiation and melanoma. Wellstein acknowledged that bringing the test to clinics will require industry partners, and that search is the next step.
A single tube of blood, drawn from a liver transplant patient, may soon be enough to show whether the new organ is in trouble and which of its cells are being hurt. That is the finding from researchers at Georgetown University and MedStar Health, published June 17 in the journal Nature Communications.
The study describes an early step toward a liquid biopsy for transplant patients. Liver transplant is a lifesaving operation, but a significant number of recipients experience rejection or other complications. The team's approach aims to catch those problems at their earliest stage, so treatment can be tailored before the organ fails. If it works as hoped, it would largely remove the need for more invasive testing.
The stakes are unusually high with the liver. Kidney patients can be supported with dialysis when an organ falters, but no machine or treatment can keep a patient alive once the liver fails. Donor livers are also in limited supply, which makes protecting each transplanted organ a priority, said co-author Alexander Kroemer, MD, PhD, a transplant surgeon at MedStar Georgetown University Hospital and director of the Center for Translational Transplant Medicine at Georgetown University Medical Center.
A new liver can be damaged in several ways. The transplant process itself can injure it, strain neighboring organs and set off an immune response. Doctors can already use blood tests to detect possible damage, and genetic testing to tell whether injured cells come from the donated liver or the patient's own body. But pinning down the precise cause usually takes costly imaging or invasive follow-up such as a liver biopsy.
The new method reads DNA fragments found in the debris of dying cells circulating in the blood. Anton Wellstein, MD, PhD, a professor of oncology and pharmacology at Georgetown's Lombardi Comprehensive Cancer Center and senior author, said his team found that chemical signatures on those fragments reveal the cell type they came from, and where, in precise detail. "What's new is that we can now figure out the cellular origin of the damage," he said, whether in the transplanted organ or in other tissues of the host that are damaged or threatened.
Because a blood draw is easy, the test can be repeated often, which would help doctors monitor patients and spot trouble early. Kroemer offered an example of what that could change: if the biliary compartment of the liver were injured but not the hepatocellular compartment, clinicians could choose a more personalized treatment. He also said the blood test is potentially more accurate than a needle biopsy, which evaluates only one small core of tissue and so risks sampling bias, since it does not examine the whole liver.
The work began seven years ago, when the researchers did not know whether cell damage could be detected in blood samples at all. "It was amazing how well it worked," Wellstein said. The project was supported by a $2.5 million grant from the National Institutes of Health and started as a research project by first author Megan McNamara, an MD/PhD student at Georgetown supported by an NIH-funded training grant.
Georgetown has filed patent applications on the technology, naming Wellstein, Kroemer and McNamara as co-inventors. The group is studying further uses, including other organ transplants, patients receiving radiation therapy for breast cancer, and melanoma treatment. It is also looking for partners to bring the test to clinics. "We can make the discovery -- that's where academia comes in -- but if you want to translate it for use in transplantation, it has to go to industry," Wellstein said.
Other authors include Sidharth S. Jain, Amber J. Kiliti, Marcel O. Schmidt, A. Patrick McDeed and Anna T. Riegel at Georgetown, and Kesha Oza, Vinona Muralidaran, Digvijay Patil and Yuki Cui at MedStar Health. The additional authors report no personal financial interests related to the study. Next comes the search for a commercial partner and the extension to other conditions.
Citas Notables
What's new is that we can now figure out the cellular origin of the damage.— Anton Wellstein, MD, PhD, Georgetown Lombardi Comprehensive Cancer Center
With needle biopsies, there's always the potential for sampling bias, because you're not sampling the whole liver.— Alexander Kroemer, MD, PhD, MedStar Georgetown University Hospital
Quieres la nota completa?
Lee el original en News-Medical.net ↗
Science & Space